started · updated
South Korean government plans measures to stabilize essential medicine supply
The South Korean Ministry of Health and Welfare is considering expanded support to prevent supply disruptions of essential medicines. To ensure stability, the government may designate certain products as "exit-prevention medicines" or apply policy premiums, which involve adjusting drug prices to reflect production costs and providing additional compensation to manufacturers.
A primary focus is on plasma-derived products, such as intravenous immunoglobulin (IVIG), which are critical for patients with weakened immune systems. These medicines are particularly vulnerable to external factors like infectious disease outbreaks or geopolitical conflicts. Experts note that while increasing drug price support impacts health insurance finances, the medical and social costs of supply shortages—including increased hospitalizations and emergency room visits—are significantly higher.
Separately, the Korean Pharmaceutical Association has raised concerns regarding medical accessibility in underserved areas. While the government is reviewing ways to relax 24-hour operating standards for over-the-counter medicine retailers, the Association argues that increasing sales points is less effective than providing professional pharmacist consultations and transportation support for elderly residents to reach medical facilities.
Entities
Korean Pharmaceutical Association · Ministry of Health and Welfare · South Korea